NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis $8.16 -0.52 (-5.99%) Closing price 09/15/2026 04:00 PM EasternExtended Trading$8.00 -0.17 (-2.02%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Phathom Pharmaceuticals Stock (NASDAQ:PHAT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PHAT alerts:Sign Up Key Stats Today's Range$8.10▼$8.6650-Day Range$8.16▼$12.6152-Week Range$8.07▼$18.31Volume1.64 million shsAverage Volume974,819 shsMarket Capitalization$660.14 millionP/E RatioN/ADividend YieldN/APrice Target$21.25Consensus RatingModerate Buy Company Overview Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s primary product is Voquezna (vonoprazan), a potassium-competitive acid blocker designed to suppress gastric acid production through a mechanism distinct from traditional proton pump inhibitors. In the United States, Voquezna is approved for use in combination regimens to eradicate Helicobacter pylori (H. pylori) infection in adults. It is also approved for the healing and maintenance of healing of erosive esophagitis and for relief of associated heartburn, as well as for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease. Phathom was founded in 2019 to develop and commercialize vonoprazan-based therapies in the United States. The company is headquartered in Buffalo Grove, Illinois, and has focused its commercial and development activities primarily on the U.S. gastrointestinal market. Terrie Curran serves as Phathom Pharmaceuticals’ president and chief executive officer.AI Generated. May Contain Errors. Read More Phathom Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScorePHAT MarketRank™: Phathom Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 297th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPhathom Pharmaceuticals has a consensus price target of $21.25, representing about 160.4% upside from its current price of $8.16.Amount of Analyst CoveragePhathom Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Phathom Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($0.27) to $1.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -6.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -6.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Phathom Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.76% of the float of Phathom Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 11.01, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently decreased by 8.07%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.68 News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Phathom Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders9.33% of the stock of Phathom Pharmaceuticals is held by insiders.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAT Stock News HeadlinesBrokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) PT at $21.25September 16 at 3:29 AM | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Research Coverage Started at Leerink PartnersSeptember 12, 2026 | americanbankingnews.comWashington Is Broke—Could YOUR Savings Be Next?The Department of Justice recently argued in court that cash is not legally property, raising new questions for savers as federal debt continues to climb. Your IRA, 401k, and bank accounts are not hidden from view, prompting some Americans to look for ways to keep more control over their own wealth. A free information kit outlines three strategies people are considering to help shield their savings from future policy changes.September 16 at 1:00 AM | Priority Gold (Ad)Leerink Partners initiates coverage of Phathom Pharmaceuticals with market performSeptember 10, 2026 | msn.comPHAT stock falls 7% as Leerink sees little near-term upside — CEO plays down upcoming rivalSeptember 9, 2026 | msn.comPhathom Pharmaceuticals: Specialist Economics Strengthens The Bull CaseSeptember 9, 2026 | seekingalpha.comLeerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PTSeptember 9, 2026 | marketscreener.comMPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comSee More Headlines PHAT Stock Analysis - Frequently Asked Questions How have PHAT shares performed this year? Phathom Pharmaceuticals' stock was trading at $16.59 at the beginning of the year. Since then, PHAT shares have decreased by 50.8% and is now trading at $8.16. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its quarterly earnings results on Thursday, February, 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm earned $57.58 million during the quarter, compared to the consensus estimate of $57.44 million. Read the conference call transcript. When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $182 million in an initial public offering on Friday, October 25th 2019. The company issued 9,563,157 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Phathom Pharmaceuticals' top institutional shareholders include BlackRock Inc. (5.59%), Carlyle Group Inc. (4.32%), Wasatch Advisors LP (1.64%) and Hsbc Holdings PLC (0.88%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi, Asit Parikh, Molly Henderson, James N Topper, Frank Karbe and Robert Charles Breedlove. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings2/26/2026Today9/16/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PHAT's financial health is in the Yellow zone, according to TradeSmith. PHAT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PHAT CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees371Year Founded2018Price Target and Rating Average Price Target for Phathom Pharmaceuticals$21.25 High Price Target$28.00 Low Price Target$10.00 Potential Upside/Downside+160.4%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$221.25 million Net Margins-41.34% Pretax Margin-41.34% Return on EquityN/A Return on Assets-20.81% Debt Debt-to-Equity RatioN/A Current Ratio1.92 Quick Ratio1.87 Sales & Book Value Annual Sales$175.11 million Price / Sales3.77 Cash FlowN/A Price / Cash FlowN/A Book Value($6.14) per share Price / Book-1.33Miscellaneous Outstanding Shares80,900,000Free Float73,353,000Market Cap$660.14 million OptionableOptionable Beta0.51 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PHAT) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredNNVC on Alert: FDA Validation and Outperform Rating!NanoViricides (NYSE: NNVC) just landed FDA Rare Pediatric Disease Designation for NV-387 in Measles, adding to...Equiscreen | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAT Stock Alerts